FAQ on Lantern Pharma's Completion of Phase 2 HARMONIC Trial Enrollment in Japan

What is the Phase 2 HARMONIC trial about?

The Phase 2 HARMONIC trial evaluates LP-300 in combination with carboplatin and pemetrexed for treating never-smoker non-small cell lung cancer (NSCLC) patients who have progressed after tyrosine kinase inhibitors.

Why is the completion of enrollment in Japan significant?

Completing enrollment ahead of schedule in Japan validates Lantern Pharma’s international expansion strategy into regions with a higher prevalence of never-smoker NSCLC, such as Japan and Taiwan.

How many patients are enrolled in the global trial?

The global trial aims to enroll approximately 90 patients, with 10 already enrolled across five sites in Japan, including the National Cancer Center Japan.

What does Lantern Pharma’s RADR platform do?

Lantern Pharma’s RADR platform is an AI and machine learning system that leverages over 100 billion oncology-focused data points and 200+ advanced ML algorithms to accelerate oncology drug discovery and development.

What are the potential benefits of LP-300?

Early U.S. data showed an 86% clinical benefit rate with LP-300, including a durable complete response lasting nearly two years, indicating its potential as a life-changing therapy for NSCLC patients.

Where else is the HARMONIC trial being conducted?

Alongside Japan, the trial is also being conducted in Taiwan and the U.S., targeting regions with higher prevalence of never-smoker NSCLC.

What is the estimated market potential of Lantern Pharma’s pipeline?

Lantern Pharma’s AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD.

How can investors stay updated on Lantern Pharma’s progress?

Investors can find the latest news and updates relating to Lantern Pharma (LTRN) in the company’s newsroom at https://ibn.fm/LTRN.